SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Research and development (R&D) expenses: R&D expenses were $81.8 million and $58.8 million for the quarters ended December 31, 2024 and 2023, respectively. R&D expenses were $281.4 million and $210.8 ...
Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –– ...
Kennedy, to the Commissioner of Texas Agriculture, Sid Miller, everyone is talking about water, and what’s going inside it.
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
Today’s 6 in the City segment features host Stephanie McCoy and guest Dr. Jordan Heimer, DMD, the Head of Restorative for ...
1d
GlobalData on MSNFDA removes clinical hold on Entrada’s Duchenne therapyEntrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Jae Hyun Park, DMD, PhD, was selected to be the next editor-in-chief of the American Journal of Orthodontics and Dentofacial Orthopedics and AJO-DO Clinical Companion, effective June 1.
Mitchell: Officially, by the first birthday, or within six months of the first tooth’s coming in. The first appointment is ...
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results